Comparison of Two Commercial Molecular Tests and a Laboratory-Developed
We compared the ability of 2 commercial molecular amplification assays (RealTime SARS-CoV-2 on the m2000 [abbreviated ACOV; Abbott] and ID Now COVID-19 [abbreviated IDNOW; Abbott]) and a laboratory-developed test (modified CDC 2019-nCoV reverse transcriptase PCR [RT-PCR] assay with RNA extraction by eMag [bioMérieux] and amplification on QuantStudio 6 or ABI 7500 real-time PCR system
SEOUL, South Korea, July 30, /PRNewswire/ -- Seegene, Inc. announced that U.S. Food and Drug Administration (FDA) has further expanded the emergency use authorization (EUA) for its Allplex™ 2019-nCoV Assay, a real-time RT-PCR test for SARS-CoV-2, the novel coronavirus responsible for the COVID-19 disease.
SARS-CoV-2 / COVID-19 Assay and Research Solutions | Bio-Rad
20 Coronavirus Pandemic (COVID-19; -nCoV) The novel coronavirus identified as the causative agent of pneumonia cases first detected in Wuhan City, China in December, , was officially designated as SARS-CoV-2. On March 11, , WHO declared COVID-19 a global pandemic. For the latest information on the Novel Coronavirus COVID-19 /
PDF] The Allplex 2019-nCoV (Seegene) assay: which performances are
The Allplex 2019-nCoV (Seegene) assay appears as a reliable method, but additional evaluations using more samples are needed. Several commercial assays for SARS-CoV-2 RT-PCR are available but few of them were assessed. We evaluate the Allplex 2019-nCoV (Seegene) assay using 41 nasopharyngeal samples. The rates of agreement were 92.7% and 100% with the